Granted projects
For CerTest Biotec R&D is part of its essence. In addition to carrying out research with its own funds, the company CerTest Biotec has been the beneficiary of various competitive grants and has been awarded innovative public procurement tenders such as those detailed below.
Last project
CDTI- Science and Innovation Missions 2021: Center for Technological and Industrial Development (CDTI)
- Project title: Development of thermostable vaccines based on mRNA against the Delta variant of SARS-CoV-2.
Type of project: Pre-competitive research project in cooperation
Execution time: 15/09/2021 – 31/12/2023
Total project budget: 2.831.200,57 €
Budget for CerTest: 827.348,25 €
The objective of this project is the development of a vaccine against the Delta variant of SARS-CoV-2 based on messenger RNA (mRNA) technology that is effective in preventing the disease, and with greater stability in terms of its preservation than current vaccines. The project will facilitate the design and rapid development of other vaccines against various infectious diseases (including new pathogenic variants of coronavirus) and also for cancer immunotherapy.
Execution Date
15/09/2021 - 31/12/2023
Execution Date
September 2021 - September 2023
Execution Date
September, 2020 – October, 2022
Execution Date
Multi-year projects
Execution Date
December 2020 – June 2022
Execution Date
April- July 2020
Execution Date
July 2019 – Agoust 2020
Grants for R&D and Investment projects to face the health emergency declared by the COVID-19 disease
Execution Date
February-July 2020
Execution Date
June-December 2020
